Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Sogol KoolajiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0002-5046-487X
Sina AzadnajafabadNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0003-0105-3801
Moein YoosefiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Naser AhmadiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0003-4424-910X
Ali GolestaniNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0002-5192-0435
Erfan GhasemiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0003-1005-3272
Arezou Dilmaghani-MarandNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Negar RezaeiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0001-7047-7638
Ameneh KazemiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Nazila RezaeiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0003-4241-1783
Yosef FarziNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0002-7321-5665
Kamyar RezaeeNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Arefeh Alipour DeroueiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Maryam NasserinejadNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0003-0238-3917
Elham AbdolhamidiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0001-7679-6285
Mohammad-Mahdi RashidiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0002-7460-6000
Rosa HaghshenasNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0001-8453-8446
Azadeh Momen Nia RankohiNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.
Shirin DjalaliniaDevelopment of Research and Technology center Deputy of Research and Technology Ministry of Health and Medical Education Tehran Iran.ORCID 0000-0002-9297-0834
Farideh RaziMetabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Science Institute, Tehran University of Medical Sciences Tehran Iran.
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0009-0004-3139-197X
Farshad FarzdafarNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0001-8288-4046
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundMetabolic syndrome (MetS) is defined as clustering of 3 or more of 5 metabolic risk factors in an individual. It has been greatly using in clinical practice; although some research illustrated that it might not act as a homogenous disorder in association with cardiovascular diseases. Therefore, we aimed to investigate its prevalence and association with ischemic heart disease (IHD) and stroke.
methodsUsing Iran STEPS (STEPwise Approach to NCD [Noncommunicable Diseases] Risk Factor Surveillance) Survey 2021, the prevalence and association of MetS, with prevalence of IHD and stroke was assessed. Given the definition of MetS, it includes 16 combinations (clusters) of 5 risk factors; we aggregated them into 6 groups and evaluated their association with prevalence of IHD and stroke.
resultsOverall, 54.19% of total population had MetS, where the most prevalent criterion was elevated waist circumference. MetS was associated with 1.70 times greater adjusted odds ratio (OR) of IHD prevalence (95% CI, 1.40-2.07). A closer look reveals that the greatest OR of IHD prevalence was observed in individuals with all 5 risk factors or 4 risk factors including both elevated blood pressure and fasting plasma glucose with ORs of 6.69 (3.52-12.68) and 6.38 (3.38-12.03), respectively, compared with individuals with none of the risk factors (0 components).
conclusionsThe association of MetS cluster with IHD and stroke prevalence varied. In addition to the dose-response relationship, the clusters characterized by both elevated BP and FPG are the most critical for targeting preventive and therapeutic measures.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Subgroups With Metabolic Syndrome Show Different Association With Ischemic Heart Disease and Stroke; Findings of Iran STEPS Survey 2021. · full record | OpenQuestion